Aventis Lovenox Patent Defense: Re-Issuance Higher Priority Than Stay
Executive Summary
Aventis' Lovenox generic defense remains centered on the re-issuance of an enoxaparin patent as the company defends the original version against potential generic competition
You may also be interested in...
Lovenox Patent Re-Issuance Denied: Aventis To Submit Response Shortly
Aventis plans to submit additional information on Lovenox to the Patent & Trademark Office after the agency denied re-issuance of a patent central to the company's defense against enoxaparin generics
Lovenox Patent Re-Issuance Denied: Aventis To Submit Response Shortly
Aventis plans to submit additional information on Lovenox to the Patent & Trademark Office after the agency denied re-issuance of a patent central to the company's defense against enoxaparin generics
Sanofi/Aventis Merger Would Create Top 10 U.S. Pharma Company
A Sanofi/Aventis merger combination would break Sanofi into the top 10 ranking of U.S. pharmaceutical companies